Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio Inc (PALI) is a clinical-stage biopharmaceutical company advancing therapies focused on gastrointestinal health through intestinal barrier protection. This page provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing clinical trial progress, partnership announcements with research institutions, SEC filings, and updates on IBD treatment candidates. Our curated collection ensures efficient tracking of material events influencing the company’s trajectory.
Users will find updates categorized by clinical research advancements, intellectual property developments, and financial disclosures. Regular updates reflect Palisade Bio’s commitment to addressing ulcerative colitis, Crohn’s disease, and related inflammatory conditions through targeted therapeutic strategies.
Bookmark this page for streamlined access to verified PALI news. Combine our updates with Stock Titan’s financial tools for comprehensive market research.
Palisade Bio announced the grant of equity options to two new non-executive employees, totaling 93,000 shares, under its 2021 Inducement Plan. The options, set at the closing stock price on the grant date, vest quarterly over three years. The company focuses on developing therapies for gastrointestinal complications, with its lead drug candidate, LB1148, in ongoing Phase 3 and Phase 2 clinical trials. The potential of LB1148 to improve postoperative bowel function and reduce abdominal adhesions positions the company as a significant player in gastrointestinal therapeutics.
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced participation in a fireside chat by CEO Tom Hallam, Ph.D., at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at 11:30 AM ET in New York, NY. The chat will be followed by one-on-one meetings with investors. A live video webcast will also be available for 90 days on the Palisade Bio website. The company focuses on therapeutics for gastrointestinal complications, with its lead program, LB1148, in Phase 3 studies.
Palisade Bio, Inc. (Nasdaq: PALI) announced a strategic review leading to initiatives aimed at streamlining operations and reducing expenses by over $1.5 million annually. This includes a 20% workforce reduction to extend the capital runway necessary for advancing its lead clinical program, LB1148. The company is currently enrolling patients in a pivotal Phase 3 study focused on postoperative bowel function, targeting completion in 18-24 months. The CEO believes these measures will enhance financial stability and shareholder value as they progress through clinical studies.
Palisade Bio (Nasdaq: PALI) announced a live moderated webcast on September 16, 2022, to discuss its pivotal Phase 3 study of LB1148, aimed at assessing the safety and efficacy for postoperative return of bowel function.
The study will enroll approximately 600 patients, focusing on recovery time after gastrointestinal surgeries. Previous Phase 2 data showed a 1.1-day improvement in bowel function recovery. This initiative reflects Palisade’s strategy to enhance gastrointestinal therapies and may set new standards for postoperative care.
Palisade Bio (Nasdaq: PALI) has announced the dosing of its first patient in a Phase 3 clinical study of LB1148, aimed at enhancing the return of bowel function in adults post-gastrointestinal surgery. This pivotal study will involve around 600 patients and mirrors a previous Phase 2 study that showed a significant 1.1-day improvement in bowel function recovery. LB1148, a novel oral formulation of a digestive enzyme inhibitor, is positioned to potentially set new standards in postoperative care by reducing complications such as abdominal adhesions.
Palisade Bio (Nasdaq: PALI) announced the completion of an underwritten public offering, generating approximately $13.8 million in gross proceeds. This offering included 49.36 million shares of common stock, 1,460 shares of Series B convertible preferred stock, and 55.2 million warrants at an exercise price of $0.25 each. The offering involved the full exercise of the underwriter’s over-allotment option. Ladengurg Thalmann & Co. acted as the sole book-running manager for this offering, which was registered with the SEC.
Palisade Bio (Nasdaq: PALI) reported its Q2 2022 results, highlighting the initiation of a Phase 3 trial for LB1148, aimed at enhancing bowel function recovery post-surgery. The company secured $12 million in funding through an underwriting agreement, extending its cash runway into 2023. Financially, Palisade recorded a net loss of $2.3 million in Q2, a significant decrease from $31.7 million in the previous year, while R&D expenses rose to $1.3 million, indicative of ongoing clinical efforts. The company anticipates increased R&D costs as it progresses with its clinical trials.
Palisade Bio (Nasdaq: PALI) announced a public offering priced at approximately $12 million before deductions. The offering includes 42.16 million shares of common stock and 1,460 shares of Series B convertible preferred stock, with 48 million Series 1 and Series 2 Warrants at an exercise price of $0.25 per share. The transaction is expected to close around August 16, 2022, pending customary conditions. Ladenburg Thalmann & Co. is the book-running manager, with a 45-day option for the underwriter to purchase additional shares.
Palisade Bio has commenced its Phase 3 study of LB1148, focusing on restoring bowel function in patients post-gastrointestinal surgery. The trial aims to enroll around 600 patients, assessing the efficacy of LB1148 in accelerating gastrointestinal recovery. Previous Phase 2 studies indicated a 1.1-day improvement in bowel function. The company emphasizes rapid patient enrollment over the next 18-24 months, with LB1148 potentially setting a new standard of care for many abdominal surgery patients.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
